These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 12826842)

  • 41. Interchangeability of activated clotting time values across different point-of-care systems.
    Thenappan T; Swamy R; Shah A; Nathan S; Nichols J; Bond L; Jolly N
    Am J Cardiol; 2012 May; 109(9):1379-82. PubMed ID: 22341924
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Comparison of five point-of-care prothrombin and activated partial thromboplastin time devices based on age of blood sample.
    Searles B; Nasrallah F; Graham S; Lajara RB
    J Extra Corpor Technol; 2002 Sep; 34(3):178-81. PubMed ID: 12395962
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Evaluation of CoaguChek Pro ACT in cardiac catheterization laboratory.
    Müller-Bardorff M; Strasser RH; Schön S; Westphal E; Mullican WS; Dauerman HL; Schwab M; Katus HA
    Clin Chim Acta; 2001 May; 307(1-2):135-8. PubMed ID: 11369348
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A novel thrombelastograph tissue factor/kaolin assay of activated clotting times for monitoring heparin anticoagulation during cardiopulmonary bypass.
    Chavez JJ; Foley DE; Snider CC; Howell JC; Cohen E; Muenchen RA; Carroll RC
    Anesth Analg; 2004 Nov; 99(5):1290-1294. PubMed ID: 15502019
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The impact of heparin concentration and activated clotting time monitoring on blood conservation. A prospective, randomized evaluation in patients undergoing cardiac operation.
    Despotis GJ; Joist JH; Hogue CW; Alsoufiev A; Kater K; Goodnough LT; Santoro SA; Spitznagel E; Rosenblum M; Lappas DG
    J Thorac Cardiovasc Surg; 1995 Jul; 110(1):46-54. PubMed ID: 7609568
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Comparison of activated clotting times measured using the Hemochron Jr. Signature and Medtronic ACT Plus during cardiopulmonary bypass with acute normovolemic haemodilution.
    Lee JM; Park EY; Kim KM; Won JC; Jung TK; Lee SK
    J Int Med Res; 2018 Feb; 46(2):873-882. PubMed ID: 28974132
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The activated coagulation time: suitability for monitoring heparin effect and neutralization during pediatric cardiac surgery.
    Martindale SJ; Shayevitz JR; D'Errico C
    J Cardiothorac Vasc Anesth; 1996 Jun; 10(4):458-63. PubMed ID: 8776637
    [TBL] [Abstract][Full Text] [Related]  

  • 48. In vitro effects of aprotinin on activated clotting time measured with different activators.
    Wang JS; Lin CY; Hung WT; Thisted RA; Karp RB
    J Thorac Cardiovasc Surg; 1992 Oct; 104(4):1135-40. PubMed ID: 1383640
    [TBL] [Abstract][Full Text] [Related]  

  • 49. How does the age of a blood sample affect it's activated clotting time? Comparison of eight different devices.
    Searles B; Nasrallah F; Darling E; Yarcusko S
    J Extra Corpor Technol; 2002 Sep; 34(3):175-7. PubMed ID: 12395961
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Heparin monitoring during cardiac surgery. Part 2: Calculating the overestimation of heparin by the activated clotting time.
    Raymond PD; Ray MJ; Callen SN; Marsh NA
    Perfusion; 2003 Sep; 18(5):277-81. PubMed ID: 14604243
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Measurement of activated clotting time in children--comparison of the Celite i-STAT ACT with the Medtronic ACT II.
    Hug MI; Di Bernardo S; Berger F; Bauersfeld U; Weiss M
    Acta Anaesthesiol Scand; 2004 Feb; 48(2):211-7. PubMed ID: 14995944
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Activated clotting time in inpatient diagnostic and interventional settings.
    Dalton H; Martin M; Garcia-Filion P; Shavelle D; Huang PH; Clark J; Beinart S; Israel A; Korpi-Steiner N
    J Thromb Thrombolysis; 2022 Nov; 54(4):660-668. PubMed ID: 35731496
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Monitoring of heparin-induced anticoagulation with kaolin-activated clotting time in cardiac surgical patients treated with aprotinin.
    Wang JS; Lin CY; Hung WT; Karp RB
    Anesthesiology; 1992 Dec; 77(6):1080-4. PubMed ID: 1281624
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Reliability of the heparin management test for monitoring high levels of unfractionated heparin: in vitro findings in volunteers versus in vivo findings during cardiopulmonary bypass.
    Mertzlufft F; Koster A; Hansen R; Risch A; Kuppe H; Kübel B; Crystal GJ
    Anesthesiology; 2000 Jun; 92(6):1594-602. PubMed ID: 10839908
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Relationship between the heparin management test and the HemoTec activated clotting time in patients undergoing percutaneous coronary intervention.
    Tsimikas S; Beyer R; Hassankhani A
    J Thromb Thrombolysis; 2001 May; 11(3):217-21. PubMed ID: 11577260
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of low doses of aprotinin on clotting times activated with celite and kaolin.
    Farooqi N; De Hert S; Vlaeminck R; De Bakker A; Govaerts E; Vermeyen K
    Acta Anaesthesiol Belg; 1993; 44(3):87-92. PubMed ID: 7508668
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Monitoring high-dose heparin levels by ACT and HMT during extracorporeal circulation: diagnostic accuracy of three compact monitors.
    Giavarina D; Carta M; Fabbri A; Manfredi J; Gasparotto E; Soffiati G
    Perfusion; 2002 Jan; 17(1):23-6. PubMed ID: 11817524
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Monitoring activated clotting time for combined heparin and aprotinin application: an in vitro evaluation of a new aprotinin-insensitive test using SONOCLOT.
    Ganter MT; Dalbert S; Graves K; Klaghofer R; Zollinger A; Hofer CK
    Anesth Analg; 2005 Aug; 101(2):308-314. PubMed ID: 16037133
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Measurement of activated coagulation time in children: evaluation of the blood-saving kaolin i-STAT activated coagulation time technique in pediatric cardiac anesthesia.
    Ulmer FF; Baulig W; Béttex D; Spielmann N; Bürki C; Weiss M
    J Cardiothorac Vasc Anesth; 2011 Jun; 25(3):395-401. PubMed ID: 21376632
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Measurement of the activated clotting time during cardiopulmonary bypass: differences between Hemotec ACT and Hemochron Jr apparatus.
    Svenmarker S; Appelblad M; Jansson E; Häggmark S
    Perfusion; 2004; 19(5):289-94. PubMed ID: 15506033
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.